What Tmunity is and isn’t changing after deaths that grounded its PSMA CAR program
Same targets, but more stringent patient selection protocols and optimized cell engineering
After neurotoxicity events, Tmunity is adopting more stringent patient selection protocols for its solid tumor CAR T cell trials and optimizing cell engineering, but it’s sticking with the same targets.
Jun 5, 2021 | 1:18 AM GMT
In the aftermath of three program-ending neurotoxicity events, Tmunity is upping the baseline scrutiny of patients enrolling in its solid tumor CAR